ThinkstockThe U.K.’s royal family is wealthy, but likely not wealthy enough to pass up sponsorships as the heir to the thrown is born to Kate, the wife to Prince William. Or, perhaps the family…
ThinkstockPhysicians Realty Trust (NYSE: DOC) priced its initial public offering (IPO) at $11.50 a share, the low end of the expected range of $11.50 to $13.50, but the firm offered 10.4 million shares instead…
ThinkstockAbbott Laboratories (NYSE: ABT) reported second-quarter 2013 results before markets opened this morning. The drugmaker reported adjusted diluted earnings per share (EPS) of $0.46 on revenues of $5.45 billion. In the same period last…
Wikimedia CommonsJohnson & Johnson (NYSE: JNJ) reported second-quarter 2013 results before markets opened this morning. The health care giant reported quarterly adjusted diluted earnings per share (EPS) of $1.48 on revenue of $17.9 billion.…
courtesy of NBN at German WikipediaThe news around tobacco and smoking cigarettes has been dominated by the trends around the e-cigarette market in 2013, but perhaps something else is afoot here. Cigarette case volumes…
ThinkstockHealth information website WebMD Health Corp. (NASDAQ: WBMD) this morning raised its second-quarter estimates for revenues and profits, citing higher demand for its advertising and sponsorships, especially from biopharmaceutical companies. The company also boosted…
ThinkstockBiotechnology stocks have had an extremely solid first half of the year. The analysts at Cowen Group point out that expectations are very high and many of the stocks have already made big moves.…
ThinkstockIntuitive Surgical Inc. (NASDAQ: ISRG) has been the darling of momentum investors for years. Yesterday it gave short sellers the data they have waited for. Sales of its da Vinci robotic surgical system have…
ThinkstockAfter falling for three straight years, U.S. beer consumption finally leveled off last year. In 2012, the country consumed 28.2 gallons of beer for every adult of legal age. Annual beer consumption varies widely…
ThinkstockHistorically, health care spending among developed nations has grown considerably each year. However, beginning in 2010, spending has flattened. Based on figures published last week by the Organization for Economic Co-operation and Development (OECD),…
ThinkstockOn Friday after the market closed, biotech giant Amgen Inc. (NASDAQ: AMGN) made an unsolicited $120 per share bid for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) that was rejected. The company has now hired advisors…
ThinkstockAlthough Amgen Inc.’s (NASDAQ: AMGN) $10 billion offer for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) was unsolicited and not exactly a stalking horse bid, that’s what many observers expect to be the result. By turning…
ThinkstockThe world of biotech investing is always a difficult one. Often a binary event, such as a Food and Drug Administration (FDA) approval or a life-saving capital raise, is the difference between not only…
ThinkstockCancer-drug developer Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) issued a terse press release yesterday, saying it had “received and rejected” a buyout offer from Amgen Inc. (NASDAQ: AMGN) for $120 per share. Shares of Onyx…
Wikimedia CommonsIn a sign that Pfizer Inc. (NYSE: PFE) has more cash on hand than the sense to use it wisely to create new drugs, its board approved a $10 billion share buyback. Pfizer…